Resumption
FDA Reverses Course, Allows Sarepta to Resume Duchenne Gene Therapy Shipments
FDA; Sarepta Therapeutics; Duchenne muscular dystrophy; Elevidys; gene therapy; safety pause; shipment resumption
Actionable Insights Powered by AI
FDA; Sarepta Therapeutics; Duchenne muscular dystrophy; Elevidys; gene therapy; safety pause; shipment resumption